CS Evaluation Fields. Outline of Presentation. Purpose of Evaluation Field. CSv2 Title of Presentation Jan 2011 Lecture Version: 1.

Similar documents
ACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation *

Esophagus, Esophagus GE Junction, Stomach

Exercise 15: CSv2 Data Item Coding Instructions ANSWERS

Interactive Discussion of Part I CS Coding Instructions: Working the Cases

Version 2 Overview and Update CSv0202 to CSv0203

Collaborative Staging

5/8/2014. AJCC Stage Introduction and General Rules. Acknowledgements* Introduction. Melissa Pearson, CTR North Carolina Central Cancer Registry

CS Release Notes Version ORGANIZATION OF RELEASE NOTES

Collaborative Stage for TNM 7 - Revised 12/02/2009 [ Schema ]

Seventh Edition Staging 2017 Breast

Collaborative Stage Data Collection System (CSv2) Reporting Requirements Commission on Cancer (CoC) (Updated 4/8/ changes in red print)

2018 Grade PEGGY ADAMO, RHIT, CTR OCTOBER 11, 2018

Collaborative Stage Data Collection System (CSv xx) Reporting Requirements Commission on Cancer (CoC)

SEER Summary Stage Still Here!

Kidney Q&A 5/5/16 Q1: Can we please get that clarification sent with the presentation and Q&A? Also a start date for that clarification

Explaining Blanks and X, Ambiguous Terminology and Support for AJCC Staging

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1

Explaining Blanks and X, Ambiguous Terminology and Support for AJCC Staging

Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules

Collaborative Stage. Site-Specific Instructions - LUNG

Staging for Residents, Nurses, and Multidisciplinary Health Care Team

CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I

Case Scenario 1. 4/19/13 Bone Scan: No scintigraphic findings to suggest skeletal metastases.

Seventh Edition Staging 2017 Colorectum. Overview. This webinar is sponsored by. the Centers for Disease Control and Prevention.

Major Rule Changes. Donna M. Gress, RHIT, CTR Technical Editor, AJCC Cancer Staging Manual First Author, Chapter 1: Principles of Cancer Staging

AJCC 7 th Edition Staging Disease Site Webinar Colorectum

7 th Edition Staging. AJCC 7 th Edition Staging. Disease Site Webinar. Colorectum. Overview. This webinar is sponsored by

Seventh Edition Staging 2017 Melanoma. Overview. This webinar is sponsored by. the Centers for Disease Control and Prevention.

AJCC Cancer Staging 8 th Edition. Prostate Chapter 58. Executive Committee, AJCC. Professor and Director, Duke Prostate Center

Q: How do you clinically code the N if the nodes are stated to be positive on mammogram/us or other imaging? No biopsy of nodes was done.

Q: In order to use the code 8461/3 (serous surface papillary) for ovary, does it have to say the term "surface" on the path report?

4/10/2018. SEER EOD and Summary Stage. Overview KCR 2018 SPRING TRAINING. What is SEER EOD? Ambiguous Terminology General Guidelines

Kyle L. Ziegler, CTR. California Cancer Registry U.C. Davis Health System

What s New for 8 th Edition

Colon, Rectum, and Appendix. Presentation Outline. Overview Tumor Characteristics

Colon, Rectum, and Appendix

Prostate Case Scenario 1

2018 New Grade Coding Rules It s a Good Thing!

Case Scenario year-old white male presented to personal physician with dyspepsia with reflux.

Introduction & Descriptors

AJCC-NCRA Education Needs Assessment Results

Collaborative Stage for TNM 7 - Revised 06/30/2008 [ Schema ]

AJCC 7 th FAQ-1. General Rules for Staging. Question:

Minor Rule Changes. Donna M. Gress, RHIT, CTR Technical Editor, AJCC Cancer Staging Manual First Author, Chapter 1: Principles of Cancer Staging

AJCC 8 th Edition Staging. Introduction & Descriptors. Learning Objectives. This webinar is sponsored by

A Practicum Approach to CS: GU Prostate, Testis, Bladder, Kidney, Renal Pelvis. Jennifer Ruhl, RHIT, CCS, CTR Janet Stengel, RHIA, CTR

AJCC 8 th Edition Staging. Introduction & Descriptors. Learning Objectives. This webinar is sponsored by

Lung. 10/24/13 Chest X-ray: 2.9 cm mass like density in the inferior lingular segment worrisome for neoplasm. Malignancy cannot be excluded.

Kentucky Cancer Registry Spring Training 2017

1/25/13 Right partial nephrectomy followed by completion right radical nephrectomy.

Case Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors

AJCC 8 th Edition Staging. Minor Rule Changes. Learning Objectives. This webinar is sponsored by. the Centers for Disease Control and Prevention.

Change Log V1.3- v1.4

AJCC TNM STAGING UPDATES ARE YOU READY FOR TNM?

Quiz Adenocarcinoma of the distal stomach has been increasing in the last 20 years. a. True b. False

Lung /4/18. Please submit all questions concerning the webinar content through the Q&A panel.

Summary Stage 2018 (SS2018)

Thursday, August 16, :30 AM - 4:30 PM and Friday, August 17, :30 AM 12:00 PM Crowne Plaza 830 Phillips Lane Louisville, KY 40209

2018 Implementation: SEER Summary Stage 2018

Q&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series

Case Scenario 1. Pathology report Specimen from mediastinoscopy Final Diagnosis : Metastatic small cell carcinoma with residual lymphatic tissue

Coding Pitfalls 9/11/14

MCR: MANAGEMENT OF 2018 CHANGES. By: Maricarmen Traverso-Ortiz MPH, CGG, CTR

Case Scenario 1. The patient has now completed his neoadjuvant chemoradiation and has been cleared for surgery.

AJCC Cancer Staging 8 th Edition

Prostate Overview Quiz

VISUAL EDITING GUIDELINES March 2015 (revised June 2015)

Interactive Staging Bee

2011 CSv2 Reliability Study Final Report. FINAL REPORT AND RECOMMENDATIONS CSv2 RELIABILITY STUDY. September 2012

Collecting Cancer Data: Prostate Q&A. Overview. NAACCR Webinar Series June 11, 2009

Collaborative Stage for TNM 7 - Revised 07/14/2009 [ Schema ]

11/21/13 CEA: 1.7 WNL

is time consuming and expensive. An intra-operative assessment is not going to be helpful if there is no more tissue that can be taken to improve the

Q&A for Collecting Cancer Data: Unusual Sites and Histologies Thursday, October 1, 2015

2007 New Data Items. Slide 1. In this presentation we will discuss five new data items that were introduced with the 2007 MPH Coding Rules.

Outline. How to Use the AJCC Cancer Staging Manual, 7 th ed. 7/9/2015 FCDS ANNUAL CONFERENCE ST PETERSBURG, FLORIDA JULY 30, 2015.

Collaborative Staging Manual and Coding Instructions Part II: Primary Site Schema

Obtaining the diagnosis:

Completing the Puzzle AJCC TNM Staging Breast. Nicole Catlett, CTR 2017 Kentucky Cancer Registry Fall Conference, September 21 & 22, 2017

EVERYTHING YOU WANTED TO KNOW ABOUT. Robin Billet, MA, CTR, Head & Neck CTAP Member May 9, 2013

Boot Camp Case Scenarios

Case Scenario 1. Discharge Summary

Collaborative Stage Site-Specific Instructions - BREAST

CODING STAGE: TNM AND OTHER STAGING SYSTEMS. Liesbet Van Eycken Otto Visser

Lesson 8 Classifications

2018 Summary Stage PEGGY ADAMO, RHIT, CTR OCTOBER 11, 2018

Case Scenario 1. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised.

GUIDELINES ON PROSTATE CANCER

1 Size of Lymph Nodes Required 3883 LN Size 2. OBSOLETE - Extracapsular Extension, Lymph Nodes for Head and Neck

Registrar s Guide to Chapter 1, AJCC Seventh Edition. Overview. Learning Objectives. Describe intent and purpose of AJCC staging

NEW JERSEY STATE CANCER REGISTRY

2018 IMPLEMENTATION UPDATE: WHAT S NEW IN STAGING FOR 2018?

Chapter 2. Understanding My Diagnosis

Question: If in a particular case, there is doubt about the correct T, N or M category, what do you do?

You Want ME to Stage that Case???

Case Scenario 1 Discharge Summary Pathology Report Final Diagnosis: Oncology Consult

NAACCR Webinar Series 1

Case Scenario #1 Larynx

Coding Pitfalls 9/1/2011. Coding Pitfalls Questions. Fabulous Prizes!!! September 1, NAACCR Webinar Series 1

Case Scenario 1 Discharge Summary Pathology Report Final Diagnosis: Oncology Consult

Transcription:

CS Evaluation Fields Education and Training Team Collaborative Stage Data Collection System Version 02.03.02 (Effective date: 1/1/2011) Outline of Presentation Purpose AJCC TNM Classification Eval data items CS Tumor Size/Ext Eval CS Lymph Nodes Eval CS Mets Eval Frequently asked questions Conclusion 2 Purpose of Evaluation Field Document how the highest T, N or M category was established (clinical vs pathologic) Document treatment effect on tumor. Was pre-surgical treatment effective OR worse scenario after neoadjuvant treatment? Best question to ask yourself when assigning Eval codes is: What did I base the T, N or M on? 3 Lecture Version: 1.0 1

Purpose of Evaluation Field Assign TNM data elements as either: Clinical (c) Pathologic (p) Post neoadjuvant pathologic (yp) Autopsy (a) 4 The AJCC TNM Classification First edition released in 1978 AJCC 7th edition (current) effective for all cancer cases diagnosed 1/1/2010 and after One of several cancer staging systems used worldwide Most clinically useful staging system Maintained by the American Joint Committee on Cancer (AJCC) and the International Union Against Cancer (UICC) 5 6 Defining the TNM System: T T: Extent of primary tumor sometimes includes size Relevant CS data elements: CS Tumor Size CS Extension (direct CS Extension of primary tumor and CS Extension within primary) CS Tumor Size/Ext (method of Evaluating T) Relevant Site Specific Factors Examples: T for Colon schema based only on CS Extension T for Kidney schema based on CS Tumor Size and CS Extension T for Lung schema based on Tumor Size, Extension and Site Specific Factor 1 Lecture Version: 1.0 2

7 Defining the TNM System: N N: Involvement of regional CS Lymph Nodes Relevant CS data elements: CS Lymph Nodes CS Lymph Nodes Eval Regional Nodes Positive Regional Nodes Examined Relevant Site Specific Factors Example: For Lung, N is based on the Lymph node code Example: For Colon, 1-3 positive CS Lymph Nodes are a N1, 4+ CS Lymph Nodes are a N2 Example: For Pharyngeal Tonsil, the size of the largest positive lymph node will determine N1, N2(a, b, or c) or N3 Defining the TNM System: M M: Presence or absence of distant metastases Relevant CS data elements: CS Mets at Dx If there are Bone, Brain, Liver or Lung mets, the new CS Mets at Dx fields need to be 1 (yes) as applicable CS Mets Eval 8 THE EVAL CODES 9 Lecture Version: 1.0 3

Clinical Code 0 (c) Physical Exam Imaging (i.e. CT, MRI, PET) Other non-invasive methods of examining tissues 10 Evaluation Codes Clinical code 1 (c) Scopes Observations at surgery i.e. Surgical exploration of liver during colon resection Diagnostic biopsies Do not use code 1 for FNA s or needle core biopsies that are histologic confirmation only 11 12 Evaluation Codes Scopes and the Evaluation codes Performed to evaluate presenting symptoms Patient presents with dysphasia. Endoscopy done to determine cause and malignancy found in EGJ junction (use Eval code 1 if no other workup) Performed to confirm suspected malignancy Patient noted to have lung mass on CT scan with extension to mediastinum, suspect carcinoma. Bronchoscopy done, which confirms small cell carcinoma. Extension based on CT scan. (Use Eval code 0) Performed to evaluate extent of suspected malignancy Patient noted to have esophageal mass on CT scan. Endoscopy done which shows mass in intrathoracic esophagus. Extension to bronchus noted. (Use Eval code 3 since this is a T4b, and is the highest T category) Lecture Version: 1.0 4

Evaluation Codes Pathologic Code 3 (p) Based on surgical resection (no or unknown prior neoadjuvant treatment) OR Based on biopsy that determines the highest applicable T, N or M category 13 Clinical Code 5 (c) Neoadjuvant treatment received Clinical evidence unless pathologic evidence is more extensive than clinical Evaluation Codes 14 15 Evaluation Codes y Pathologic Code 6 (yp) Neoadjuvant treatment received AND Pathologic evidence at surgery is more extensive than clinical evidence before treatment Neoadjuvant therapy given, pathologic evidence available, clinical evaluation prior to neoadjuvant therapy not available Lecture Version: 1.0 5

Evaluation Codes Autopsy Code 2 (p) Autopsy performed Prior knowledge of malignancy (suspected OR diagnosed) Autopsy Code 8 (a) Autopsy performed Malignancy diagnosed at autopsy with no prior knowledge of malignancy (unsuspected OR undiagnosed) 16 Clinical Code 9 (c) Unknown Unknown how T, N or M determined Defaults to clinical (c) 17 CS TUMOR SIZE/EXT EVAL CODES 18 Lecture Version: 1.0 6

CS Tumor Size/Ext Eval Common table used for all schemas except: 1 not applicable table (can only use code 9) (AdnexaUterineOther, Brain, CNSOther, DigestiveOther, EndocrineOther, EyeOther, GenitalFemaleOther, GenitalMaleOther, HemeRetic, IllDefinedOther, IntracranialGland, KaposiSarcoma, Lymphoma, MelanomaSinusOther, MiddleEar, MyelomaPlasmaCellDisorder, PharynxOther, RespiratoryOther, SinusOther, Trachea, UrinaryOther) 5 individual CS Tumor Size/Ext Eval Tables 1) Bladder; 2)Lung; 3)Lymphoma; 4)Prostate 5) Includes the following schemas: AdrenalGland, LacrimalSac, GIST, Head & Neck Melanomas, LymphomaOcularAdnexa 19 The Common Table for CS Tumor Size/Ext Eval 20 CS Tumor Size/Ext Eval 21 T based on farthest CS Extension or CS Tumor Size Tumor size only Example: T1 and T2 lesions in Breast Extension only Example: All T categories in Colon Tumor size or CS Extension Example: T3 lesions in Breast See CS Manual, Part I, Section 1, v02.03.02: Appendix 3: Schema Names, Site Codes, and Other Characteristics of CS Schemas, pgs. I:96-100 for schemas where Tumor Size is a factor in determining T Lecture Version: 1.0 7

CS Tumor Size/Ext Eval Why are Tumor Size and Extension evaluated together? In many sites, the CS Tumor Size and CS Extension are used together to determine T Example: 2 cm tumor confined to Breast Not all schemas use Tumor Size in determining T In those sites where TS is used, it is usually for localized lesions only T1 and T2 lesions T3 lesions for some schemas (i.e. Breast & Lung) 22 CS Tumor Size/Ext Eval Even in schemas where CS Tumor Size is used, a further CS Extension code can override CS Tumor Size Examples: Breast, 7 cm mass (T3) with invasion of chest wall (T4a) Lung, 7 cm mass (T3) with SVC syndrome (T4) Kidney, 6 cm mass (T2) with renal artery involvement (T3a) 23 It s very important to know where your highest T is coming from when CS Tumor Size and CS Extension both factor into T CS Tumor Size/Ext Eval Clinical code 1 No surgery of primary tumor Biopsy results in further (more extensive) information regarding CS Extension Many times a biopsy is done to confirm diagnosis and NOT evaluate CS Extension (use code 0 in this case) Example: CT scan shows 6 cm kidney tumor, suspect renal cell carcinoma; biopsy confirms renal cell carcinoma. Eval code of 0 would be assigned since T would be based on CS Tumor Size from CT scan 24 Lecture Version: 1.0 8

CS Tumor Size/Ext Eval When you have a T category based on pathologic evaluation and a T category based on clinical evaluation: Assign the appropriate clinical Eval code when the clinical CS Extension maps to a higher T category Assign the appropriate pathologic code when the pathologic and clinical CS Extension map to the same T category and there is no neoadjuvant therapy Same principle applies when you have T subcategories (i.e. T1a, T1b, T1c) 25 CS Tumor Size/Ext Eval 26 Example (from discussion on previous slide) Bladder: Cystectomy shows direct CS Extension to the pelvic wall Extension code 750 Maps to T4b CT Abd/Pelvis shows further contiguous CS Extension to the sigmoid colon Extension code 801 Maps to T4b Assign CS Tumor Size/Ext Eval code of 3 even though the clinical CS Extension is a higher code. Both CS Extension codes map to the same T category CS TUMOR SIZE/EXT EVAL: SCHEMA SPECIFIC TABLES 27 Lecture Version: 1.0 9

The Not Applicable Table for CS Tumor Size/Ext Eval 28 CS Tumor Size/Ext Eval Table for Bladder Additional note added stating that a TURBT (transurethral resection of bladder tumor) is CLINICAL and should be coded 1 Codes and code definitions same as common table 29 CS Tumor Size/Ext Eval Table for Bladder 30 Lecture Version: 1.0 10

CS Tumor Size/Ext Eval Table for Lung AJCC 6th edition Code 1 was mapped to pathologic AJCC 7th edition Code 1 now maps to clinical CS Tumor Size/Ext Eval table for Lung is the common table 31 CS Tumor Size/Ext Eval Table for Lung 32 CS Tumor Size/Ext Eval Table for Lung 33 I noticed that three factors are used to derive T in Lung. How do I determine the Eval code? Tumor Size, Extension and Site Specific Factor 1 (separate tumor nodules) determine T Most of the time CS Tumor Size/Ext Eval will be based on Tumor Size and Extension If you have separate tumor nodules and it raises the T value, then take Site Specific Factor 1 into account for assigning CS Tumor Size/Ext Eval Lecture Version: 1.0 11

CS Tumor Size/Ext Eval Table for Lung Site Specific Factor 1 000, 999 Site Specific Factor 1 010, 040 Site Specific Factor 020, 030 34 CS Tumor Size/Ext (T1) CS Tumor Size/Ext (T2) CS Tumor Size/Ext (T3) CS Tumor Size/Ext (T4) CS Tumor Size/Ext (TX) T1 (Eval based on CS Tumor Size/Ext) T2 (Eval based on CS Tumor Size/Ext) T3 (Eval based on CS Tumor Size/Ext) T4 (Eval based on CS Tumor Size/Ext) TX (Eval based on CS Tumor Size/Ext) T3 (Eval based on Site Specific Factor1) T3 (Eval based on Site Specific Factor1) T3 (Eval based on best info available ) T4 (Eval based on CS Tumor Size/Ext) T3 (Eval based on Site Specific Factor1) T4 (Eval based on Site Specific Factor1) T4 (Eval based on Site Specific Factor1) T4 (Eval based on Site Specific Factor1) T4 (Eval based on best info available) T4 (Eval based on Site Specific Factor1) CS Tumor Size/Ext Eval Table for Lymphoma Code 0: Most lymphomas will have an Eval code of 0 Code 2: Added to be consistent with remaining schemas Code 3: Staging laparotomy MUST be done to assign code 35 CS Tumor Size/Ext Eval Table for Lymphoma 36 Lecture Version: 1.0 12

CS Tumor Size/Ext Eval Table for Lymphoma Why can t I use a surgical evaluation code when I have a tonsillectomy done for a tonsillar lymphoma? Only a Staging Laparotomy qualifies for a pathologic evaluation in Lymphoma Staging laparotomy: Splenectomy Abdominal exploration Liver biopsy Multiple LN biopsies 37 CS Tumor Size/Ext Eval Table for Prostate Code 0: Digital rectal examination (DRE), imaging examination, other non-invasive clinical evidence Code 1: Endoscopic examination, diagnostic biopsy (needle core biopsy), transurethral resection (TURP) 38 REMEMBER: The CS Tumor Size/Ext Eval code for a TURP is a TS/Ext Eval Table for Prostate I frequently have needle core biopsies for prostate, which is included in Code 1. Do I use that information in the Eval code? Needle core biopsies are often done to confirm diagnosis of prostate cancer, not determine CS Extension Information from DRE will override a needle core biopsy, unless further CS Extension is confirmed from the biopsy 39 Lecture Version: 1.0 13

40 CS Tumor Size/Ext Eval Table for Prostate But what about when I use CS Extension code 150, which states diagnosis is from needle core biopsy. Can I use Eval code 1 then? Use of CS Extension code 150 has the following conditions: DRE is negative Needle core biopsy done due to elevated PSA Use Eval code 1 Extension code 150 may also be used for stated as T1c In this scenario, Eval code 0 would be used since you are basing your CS Extension code on a stated as code. CS Tumor Size/Ext Eval Table for Prostate Prostate: CS Tumor Size/Ext Eval codes, cont. Code 2 :Positive biopsy reveals extraprostatic tissue involvement (CS Extension codes 410-700) Code 3: Evidence derived from autopsy (tumor suspected) Code 4: Prostatectomy performed without (or unknown) prior neoadjuvant treatment. Evaluation based on information acquired prior to treatment 41 Remember: Pathologic code 3 is different for Lymphoma and Prostate 42 Lecture Version: 1.0 14

CS Tumor Size/Ext Eval Table for Specific Schemas New schema Eval tables New chapter for AJCC 7th edition New schemas for CSv2 Staged by new schema for AJCC 7th edition Not staged for AJCC 6th edition (blank column) Applicable for the following schemas: Adrenal Gland, GIST, Lacrimal Sac and Melanomas of the Head and Neck 43 CS Tumor Size/Ext Eval Table for Specific Schemas 44 45 CS Tumor Size/Ext Eval Table for Other Schemas Multiple schemas use Site Specific Factor s to determine the T category Review information for CS Tumor Size, CS Extension and the applicable Site Specific Factor to determine your T Eval code should be based on how your highest T category was determined Conjunctiva (SSF1); MelanomaCiliaryBody (SSF2); MelanomaChoroid (SSF3); MelanomaConjunctiva (SSF2); MelanomaSkin (SSF1&2), Pleura (SSF1); Retinoblastoma (SSF1), Scrotum (SSF12); SkinEyelid (SSF6) Lecture Version: 1.0 15

CS LYMPH NODES EVAL CODES 46 CS Lymph Nodes Eval Common table used for all schemas except: 1 not applicable table (can only use code 9) (AdnexaUterineOther, Brain, CNSOther, DigestiveOther, EndocrineOther, EyeOther, GenitalFemaleOther, GenitalMaleOther, HemeRetic, IllDefinedOther, IntracranialGland, KaposiSarcoma, Lymphoma, MelanomaSinusOther, MiddleEar, MyelomaPlasmaCellDisorder, PharynxOther, Placenta, RespiratoryOther, SinusOther, Trachea, UrinaryOther) 2 individual CS Lymph Nodes Eval Tables 1) Lung 2) Includes the following schemas: AdrenalGland, LacrimalSac, GIST, Head & Neck Melanomas, LymphomaOcularAdnexa 47 The Common Table for CS Lymph Nodes Eval 48 Lecture Version: 1.0 16

49 CS Lymph Nodes Eval Based on intent of procedure Intent can be diagnostic or treatment If clinical Evaluation is positive and pathologic Evaluation disproves this, assign appropriate pathologic Eval code If neoadjuvant treatment given, assign clinical code When both clinical and pathologic Evaluation are negative, assign appropriate pathologic code Document the highest N code May or may not be the farthest involved regional CS Lymph Nodes CS Lymph Nodes Eval Clinical intent Microscopic assessment (workup) of CS Lymph Nodes intended to help choose treatment plan Tumor size and/or CS Extension is clinical and any resection of primary tumor does not meet criteria for pathologic T classification Information obtained from a lymph node excisional or incisional biopsy is part of clinical staging Example: Patient with hard lump in low neck. Endoscopic paratracheal lymph node biopsy confirms metastatic lung cancer. Patient treated with chemoradiation 50 CS Lymph Nodes Eval Pathologic intent Lymph node procedure is therapeutic (treatment) AND Resection of primary tumor meets qualifications for pathologic T classification Microscopic confirmation of highest N category without surgical resection of primary tumor 51 Lecture Version: 1.0 17

CS Lymph Nodes Eval When you have a N category based on pathologic evaluation and a higher N category based on clinical evaluation: Assign the appropriate clinical Eval code when the clinical lymph node code maps to a higher N category Assign the appropriate pathologic code when the pathologic and clinical lymph node code map to the same N category Same principle applies when you have N subcategories (i.e. N1a, N1b, N1c) 52 CS Lymph Nodes Eval Clinical code 1 Lymph node procedure is part of patient workup Used to determine course of treatment No resection of primary tumor Example: Large breast tumor on mammography. Sentinel node biopsy. Enlarged sentinel lymph node negative for malignancy. Code CS Lymph nodes Eval as 1 because the sentinel node biopsy was done to determine what type of treatment the patient should have and patient did not have surgery 53 CS Lymph Nodes Eval Pathologic Code 3 Lymph node dissection part of surgical treatment Positive FNA sufficient to use pathologic code 3 in some schemas (i.e. Prostate) Microscopic assessment of highest N always pathologic Example: FNA of 7 cm para-aortic lymph node positive for metastatic renal cell carcinoma. Assign Eval code 3 for pathologic since this will map to a N3, which is the highest N category for Kidney Parenchyma 54 Lecture Version: 1.0 18

CS LYMPH NODES EVAL: SCHEMA SPECIFIC TABLES 55 The Not Applicable Table for CS Lymph Nodes Eval 56 CS Lymph Nodes Eval Table for Lung AJCC 6th edition Code 1 was mapped to pathologic AJCC 7th edition Code 1 now maps to clinical CS Tumor Size/Ext Eval table for Lung is the common table 57 Lecture Version: 1.0 19

CS Lymph Nodes Eval Table for Lung 58 CS Lymph Nodes Eval Table for Specific Schemas New schema Eval tables New chapter for AJCC 7th edition New schemas for CSv2 Staged by new schema for AJCC 7th edition Not staged for AJCC 6th edition (blank column) Applicable for the following schemas: Adrenal Gland, GIST, Lacrimal Sac and Melanomas of the Head and Neck 59 CS Lymph Nodes Eval Table for Specific Schemas 60 Lecture Version: 1.0 20

CS Lymph Nodes Eval and Site Specific Factors Multiple schemas have Site Specific Factor s that request information on clinical CS Lymph Nodes i.e. Head and Neck Sites, Colon, Merkel Cell, Small Intestine, Stomach, Rectum, Penis, Testis This is for clinical assessment only and is based on exam or imaging The results of these Site Specific Factors are included in the stage algorithm 61 CS Lymph Nodes Eval and Site Specific Factors Determining CS Lymph Nodes Eval: The final N category code will be determined by the following: Lymph Node code Site Specific Factor code Lymph node extra tables are provided for each schema that have these two factors determining N In the event that the Site Specific Factor value raises the N category, your Eval code is based on how the Site Specific Factor was determined 62 CS METS EVAL CODES 63 Lecture Version: 1.0 21

CS Mets Eval Common table used for all schemas except: 1 not applicable table (can only use code 9) (Adnexa UterineOther, Brain, CNSOther, DigestiveOther, EndocrineOther, EyeOther, GenitalFemaleOther, GenitalMaleOther, HemeRetic, IllDefined Other, Intracranial gland, KaposiSarcoma, Lymphoma, MelanomaSinusOther, MiddleEar, MyelomaPlasmaCellDisorder, PharynxOther, RespiratoryOther, SinusOther, Trachea, UrinaryOther) 2 individual CS Mets Eval Tables 1) Includes the following schemas: Colon, Prostate, Rectum, Testis; 2) Includes the following schemas: AdrenalGland, LacrimalSac, GIST, Head & Neck Melanomas, LymphomaOcularAdnexa 64 The Common Table for CS Mets Eval 65 CS Mets Eval Concept different than T and N Assign Eval code based on best evidence in determining highest M, but not necessarily the highest mets code number Results of the procedure are used (positive vs negative), rather than type of procedure i.e. Unlike CS Tumor Size/Ext Eval and CS Lymph Nodes Eval, a surgical procedure does not automatically give you a pathologic evaluation 66 Lecture Version: 1.0 22

CS Mets Eval pm0 no longer recognized since it is impossible to rule out all possible metastatic sites CS Mets Eval is NOT based on information furthest from primary site Example: Chest x-ray negative and surgical observation during hemicolectomy show no liver metastasis. Code CS Mets Eval as 1 67 CS Mets Eval AJCC also states a case where there are no symptoms or signs of metastases is classified as clinical M0 History and physical is enough information to assign clinical mets as negative (Mets at Dx 00, CS Mets Eval 0) Extensive imaging studies are not required 68 CS Mets Eval Coding Mets at Dx 00 vs 99 and how it relates to assigning Eval field Mets at Dx can be coded based on physical exam and also if patient is treated as if they have no mets In these scenarios, CS Mets at Dx would be 00 and Eval code would be 0 (based on clinical exam) If code 99 is assigned for Mets at Dx, Eval code 0 may also be used if information from clinical exam is used Remember: Mets at Dx code 99 will map to a cm0 69 Lecture Version: 1.0 23

When Mets at Dx is 00 or 99, CS Mets Eval must be clinical Codes 0, 1, 5, 9 70 CS Mets Eval When you have CS Mets at Dx code based on pathologic (positive specimen) and a higher CS Mets at Dx code based on clinical: Assign the appropriate clinical Eval code when the clinical CS Mets at Dx code maps to a higher M subcategory Assign the appropriate pathologic code when the pathologic and clinical CS Mets at Dx code map to the same M category or subcategory This applies when you have M subcategories (i.e. M1a, M1b, M1c), since there is only the M0 and M1 category 71 CS Mets Eval Clinical code 1 Endoscopic examinations Diagnostic biopsies (including needle core or FNA) Observations at surgery Example: Abdominal exploration at time of colon resection. No mention of liver mets, along with no other clinical evidence of mets, enough information to assign Eval code 1 72 Lecture Version: 1.0 24

CS Mets Eval 73 Pathologic: Code 3 Any positive microscopic confirmation Example: FNA done for suspected pleural effusion, positive for non small cell carcinoma Complete removal of metastatic site not required Example: Liver biopsy done during colon resection, positive for metastatic adenocarcinoma. Eval code assigned is 3. Maps to pm1 CS METS EVAL: SCHEMA SPECIFIC TABLES 74 The Not Applicable Table for CS Mets Eval 75 Lecture Version: 1.0 25

CS Mets Eval Table for Specific Schemas The following sites: colon, prostate, rectum and testis have subcategories for Mets A new note has been added to clarify how to code the mets categories for these schemas 76 CS Mets Eval Table for Specific Schemas 77 CS Mets Eval Table for Specific Schemas New schema Eval tables New chapter for AJCC 7th edition New schemas for CSv2 Staged by new schema for AJCC 7th edition Not staged for AJCC 6th edition (blank column) Applicable for the following schemas: Adrenal Gland, GIST, Lacrimal Sac and Melanomas of the Head and Neck 78 Lecture Version: 1.0 26

CS Mets Eval Table for Specific Schemas 79 FREQUENTLY ASKED QUESTIONS 80 Frequently Asked Questions 81 Are there any Eval fields where the Eval code is not applicable? Answer: Yes For specific Eval fields that do not apply, code 9 for not applicable is the only code Example: HemeRetic Sometimes, there are Eval fields where one of the Eval fields is applicable and the other two are not Example: Lymphoma Lecture Version: 1.0 27

Frequently Asked Questions Are the Eval codes and code descriptions the same for all applicable schemas? Answer: No Different codes and/or code definitions used for some schemas Example: Prostate Different instructions used for some schemas Example: Bladder Difference between AJCC 6th and AJCC 7th edition Example: Lung 82 Frequently Asked Questions Is there really a difference between clinical codes 0 and 1? Answer: Yes Code 0: based on imaging or physical exam Code 1: based on information other than imaging or physical exam, which includes scopes, diagnostic biopsies, or surgical exploration 83 Frequently Asked Questions I noticed when looking at some schemas that there is a AJCC 6th edition column that is blank for the Eval fields. What does this mean? Answer: These schemas do not have an applicable AJCC 6th Edition stage Eval codes for AJCC 6th edition blank Eval codes applied for AJCC 7th edition only 84 Lecture Version: 1.0 28

Frequently Asked Questions Do I automatically assign code 9 (unknown) for my Eval field when the data item is coded unknown? Answer: No Possible to have a clinical or pathologic workup that results in an unknown value Use information available to determine best Eval code If unknown based on no information, use code 9 85 Frequently Asked Questions Are the codes hierarchal? Answer: Yes, but not in numerical order Of the 8 Eval codes, 4 have specific criteria for use (2,5,6,8) Code 9 is used when no information is available (clinical) Determine if you have a clinical or pathologic evaluation 86 Frequently Asked Questions I work in a Central Registry and have Death Certificate only cases. How do I code the Eval fields for those? Answer: 9 Code 9 for unknown/ not applicable for all Eval fields when you have a death certificate only case 87 Lecture Version: 1.0 29

Frequently Asked Questions How do I code the Eval field when CS Lymph Nodes and Mets are assigned none based on a localized lesion? Answer: Code 0 Lymph nodes and Mets at Dx coded none based on localized lesion and standard treatment Assign code 0 for clinical evaluation See CS manual, Part I, Section I, I-4 88 Frequently Asked Questions How do I code an Eval field when I use a stated as code? Answer: on best information available If no information available, use code 9 for unknown Example: Physician note: Patient is a T2N0M0, post lumpectomy/sentinel lymph node biopsy, now presents for adjuvant therapy. Assign CS Tumor Size/Ext Eval code of 3 (for surgery), CS Lymph nodes Eval code 3 and CS Mets Eval code 0 89 Frequently Asked Questions How do I code the Eval fields when all I have is a pathology report? Depends on information available from pathology report Example: Path report from surgery specimen If no information available regarding specimen (surgical vs. biopsy), code 9 for unknown 90 Lecture Version: 1.0 30

Conclusion Clinical codes (c) 0: Physical exam, imaging 1: Scopes, surgical observation 5: Neoadjuvant therapy given and clinical CS Extension equal to or greater than pathologic CS Extension 9: Unknown Autopsy code (a) 8: Autopsy, diagnosed at autopsy upon death Pathologic codes (p) 2: Autopsy, diagnosed prior to death 3: Surgical, or highest T, N or M category involved and confirmed by biopsy y Pathologic code (yp) 6: Neoadjuvant therapy given and pathologic CS Extension greater than clinical or clinical CS Extension unknown 91 CAnswer Forum Submit questions to CS Forum Located within the CAnswer Forum Provides information for all Allows tracking for educational purposes Includes archives of Inquiry & Response System 92 http://cancerbulletin.facs.org/forums/ American Joint Committee on Cancer Contact Information AJCC Web Site: www.cancerstaging.org Karen A. Pollitt Manager email: kpollitt@facs.org phone: 312-202-5313 Donna M. Gress, RHIT, CTR Technical Specialist email: dgress@facs.org phone: 312-202-5410 93 Lecture Version: 1.0 31

American Joint Committee on Cancer Contact Information Marty Madera Education Administrator email: mmadera@facs.org phone: 312-202-5287 Judy Janes AJCC Coordinator email: jjanes@facs.org phone: 312-202-5205 General Inquiries can be directed to AJCC@facs.org or CSv2@facs.org 94 Questions 95 Lecture Version: 1.0 32